Clinical trial · Interventional
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
A Multicenter Randomized Controlled Study of the Extent of Lymph Node Dissection for Advanced Right-sided Colon Cancer
NCT06986538CI-TRIAL-00090130MARCHnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective multicenter randomized controlled clinical study to explore the extent of lymph node dissection in progressive right hemicolon cancer and to elucidate the pattern of lymphatic drainage in the right hemicolon.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Right-sided Colon Cancer | — | UNRESOLVED | — |
| the Extent of Lymph Node Dissection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clearance with the left side of the SMA as the medial boundary | Procedure | — | UNRESOLVED |
| Clearance with the left side of the SMV as the medial boundary | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- SMV group
- interventionNames
- Procedure: Clearance with the left side of the SMV as the medial boundary
- type
- EXPERIMENTAL
- label
- SMA group
- interventionNames
- Procedure: Clearance with the left side of the SMA as the medial boundary
Primary outcomes (1)
- measure
- Disease-Free Survival
- timeFrame
- The third postoperative year
- description
- It is defined as the proportion of patients from the start of randomization to the end of the third year without any of the following events: disease progression, local recurrence, distant metastasis, second primary colorectal cancer, or death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: 18-75 years 2. Preoperative pathologic confirmation of adenocarcinoma 3. Tumor located in the region from the ileocecal valve to the right one-third of the transverse colon 4. American Society of Anesthesiologists (ASA) physical status classification I to III 5. Patients who have not received preoperative radiotherapy, chemotherapy, or immunotherapy 6. Preoperative imaging staging cT4N0M0 or cT3-4N+M0 7. Willing to participate in the study and sign the informed consent form Exclusion Criteria: 1. Past medical history of malignant tumor 2. Patients with multiple primary tumors 3. Patients with a history of inflammatory bowel disease or familial adenomatous polyposis 4. Patients with distant metastasis 5. Pregnant or breastfeeding women 6. History of other previous major abdominal surgery 7. Patients requiring emergency surgery (including tumor perforation, obstruction, hemorrhage, etc.) 8. Those with other clinical and laboratory conditions deemed by the investigator to be inappropriate for participation in the trial
References
Publications (0)
Data not yet available
No reference posted for this study.